| HOME >> MEDICINE >> TECHNOLOGY |
The multiple sclerosis market has been lucrative for drug companies over the last decade with limited competition and periodic price increases. However, as this dynamic is changing with increased competition, existing players are expanding their portfolios with new and improved therapies.
Monoclonal antibodies have demonstrated potent efficacy in Phase II trials, surpassing all existing therapies. However, excitement is tempered with safety concerns that include risk of malignancy and severe infections. Still, as seen with Tysabri, impressive efficacy may outweigh the risks for more severe multiple sclerosis patients.
Your key questions answered
* How well do agents in late-stage development for multiple sclerosis compare to one another and the current standard of care?
* What is the most promising treatment in development for multiple sclerosis?
* How do US neurologists perceive Gilenya and key pipeline agents as new treatments of multiple sclerosis?
Executive Summary
Strategic scoping and focus
Datamonitor key findings
Related reports
OVERVIEW
Catalyst
Summary
MARKET OVERVIEW
Product overview
Datamonitor's assessment summary
MARKETED PRODUCT PROFILES
Gilenya (fingolimod; Novartis/Mitsubishi Tanabe Pharma)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Product positioning
Physician perception of Gilenya
Clinical and commercial attractiveness
Avonex (interferon beta-1a; Biogen Idec)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Product positioning
Clinical and commerci
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |